ChronTech Pharma's rights issue and notice of EGM

ChronTech Pharma's rights issue and notice of EGM

The Board of Directors of ChronTech has on September 27 2010, based on
the authorization by the AGM, resolved to carry out a rights issue with
a maximum of 47,433,752 shares. In the rights issue 11,069,302 shares
were subscribed for and raised approx. 5.5 MSEK before transaction
costs.

21.5 %, 10,201,910 shares, have been subscribed for by using first
rights. 1.8 %, 867,392 shares, have been subscribed for without rights.

The Board of Directors of ChronTech has resolved to convene an EGM to be
held on 7 January 2011 at 2.30 pm. The Board proposes that the EGM
authorizes the Board to resolve a new issue of shares, warrants and/or
convertible debentures and with or without preferential rights for the
shareholders. The purpose with the authorization is to enable ChronTech
to raise funds corresponding to the part of the recently completed
rights issue that was not subscribed.

The notice of the EGM will be published soon.

”We had hoped to be able to get the new investors on board already in
the rights offering before Christmas, but with confidence we now look
forward to welcome new capital strong owners in ChronTech in the
beginning of the new year” says Anders Vahlne, ChronTech Pharma's CEO.

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se (anders.vahlne@ki.se)

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and
ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus
infections, i.e. chronic infections with jaundice causing viruses which
can lead to liver cirrhosis and liver cancer. ChronTech has also
developed and further develops a patent pending new type of injection
needle for a more effective uptake of DNA vaccines. ChronTech also have
part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se (http://www.chrontech.se/)

In the event of any discrepancy between the Swedish and English versions
of this press release, the Swedish version will take precedence.